Result of Annual General Meeting
31 mai 2019 10h15 HE
|
Motif Bio plc
NEW YORK, May 31, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that at the Annual...
Motif Bio plc AGM Statement
22 mai 2019 08h50 HE
|
Motif Bio plc
NEW YORK, May 22, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that at the Company’s...
Motif Bio to Evaluate Orphan Disease Opportunity for Iclaprim in Ophthalmology
22 mai 2019 02h00 HE
|
Motif Bio plc
NEW YORK, May 22, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company...
Motif Bio to Present Iclaprim Data at ASM Microbe 2019
21 mai 2019 02h00 HE
|
Motif Bio plc
NEW YORK, May 21, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that three...
Motif Bio meeting with U.S. FDA held as planned
03 mai 2019 13h25 HE
|
Motif Bio plc
NEW YORK, May 03, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, confirms that the Company met...
Motif Bio Signs Agreement with Lamellar Biomedical
01 mai 2019 02h00 HE
|
Motif Bio plc
NEW YORK, May 01, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company...
Motif Bio plc: Notice of Annual General Meeting
26 avr. 2019 02h01 HE
|
Motif Bio plc
NEW YORK, April 26, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc ("Motif Bio" or the "Company") (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics,...
Motif Bio Announces Appointment of Andrew Powell to Board of Directors
26 avr. 2019 02h00 HE
|
Motif Bio plc
NEW YORK, April 26, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB) ("Motif Bio" or the "Company"), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics,...
Motif Bio Presents New Iclaprim Data at ECCMID 2019
16 avr. 2019 02h00 HE
|
Motif Bio plc
NEW YORK, April 16, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that new...
Motif Bio Reports Fiscal Year 2018 Results
15 avr. 2019 02h00 HE
|
Motif Bio plc
NEW YORK, April 15, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced financial...